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Maternal asthma is a common disease to complicate human pregnancy. Epidemiological studies have identified that asthma during
pregnancy increases the risk of a number of poor outcomes for the neonate including growth restriction, lower birthweight,
preterm delivery, neonatal resuscitation, and stillbirth. Asthma therefore represents a significant health burden to society and
could have an impact on the lifelong health of the children of women with asthma. Our research has identified that maternal
asthma in pregnancy induces placental dysfunction and developmental perturbation in the fetus in a sex specific manner. These
alterations in development could increase the risk of metabolic disease in adulthood of children of asthmatic mothers, especially
females. In this paper, we will discuss the evidence currently available that supports the hypothesis that children of mothers with
asthma may be at risk of lifelong health complications which include diabetes and hypertension.
1. Introduction
Asthma is a noncommunicable chronic disease that has
major health, social and economic burdens in society. Asth-
ma is generally viewed as a chronic inflammatory condition
of the lung associated with airway remodelling, reversible
airway obstruction, and bronchospasm accompanied by
frequent symptoms of wheeze, cough, and shortness of
breath. It occurs in genetically susceptible individuals and
is often initiated by exposure to allergens, exercise, or viral
infection. The mechanisms leading to its symptoms can be
diverse suggesting there are numerous phenotypes of this
chronic disease [1]. The major questions related to chronic
disease are how to prevent them, eﬀectively treat disease
states, and minimise handicap. Our research work focuses
on both primary prevention for the next generation and
management of conditions in the current generation of
women. This paper considers opportunities for clinically
improving fetal outcomes in pregnancies complicated by
asthma, particularly with regard to reducing the risk of
metabolic disease in oﬀspring.
Asthma is the most prevalent chronic disease to com-
plicate pregnancy in Australia, aﬀecting 12% of pregnant
women and could increase to 20% in the next 5 years [2].
Epidemiological studies we conducted in New South Wales,
Australia have identified that maternal asthma during preg-
nancy increases the risk of a number of poor outcomes for
the neonate including growth restriction, lower birthweight,
preterm delivery, neonatal resuscitation, and stillbirth [3].
These findings are in agreement with international reports
on outcomes of pregnancies complicated by asthma [4, 5].
Asthma therefore represents a significant health burden to
society and that is expected to have an impact on the lifelong
health of the children of women with asthma.
The in utero environment can induce plastic changes in
the fetus and infant predisposing them to disease in later
life [6]. Specifically a lower birth weight has been shown
to be associated with an increased risk of cardiovascular
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and metabolic disease [6]. Furthermore perturbations in
fetal development are not just limited to intrauterine growth
restriction (IUGR) but associated with birth weights within
normal ranges [7]. Studies in laboratory animals have
identified the underlyingmechanisms associated with disease
risk in adulthood and have shown that oﬀspring at particular
risk are those animals who had restricted growth in utero
followed by accelerated compensatory growth of certain
body compartments, particularly fat mass before maturity
[8]. Studies in humans show that the association between
birthweight and later disease development is independent
of socioeconomic status and contributions of known adult
lifestyle factors that increase disease risk [7]. Together
these findings have contributed to the predictive adaptive
response (PAR) hypothesis [9] where a developing organism
predicts the external postnatal environment based on the in
utero conditions and subsequently alters its development to
optimise survival in the predicted environment. This survival
strategy increases the chance of survival to reproductive age
at the risk of health consequences in later life.
The in utero mechanisms underlying developmental
perturbation are broadly categorised into four areas: (1)
epigenetics, (2) mitochondrial function, (3) organ and tissue
development, and (4) homeostasis control systems [7].
Maternal disease during pregnancy could lead the fetus to
inappropriately adjust its development through these four
mechanisms which then leads to a mismatch between the
individual and its external environment. We have evidence
to suggest that maternal asthma during pregnancy is a disease
that contributes to placental dysfunction and developmental
perturbation in the fetus [10]. Based on our findings [3] and
a large body of work conducted by others [11], we expect
that maternal asthma has an intergenerational impact and
increases disease risk in the oﬀspring [10, 12]. Moreover,
these perturbations can be sex specific whereby females
reduce their size in response to the presence of maternal
asthma though they are not growth restricted (<10th birth-
weight centile) [13]. Male fetuses appear to continue to grow
normally in response to maternal asthma [13]. However if
asthma worsens with an exacerbation then the female fetus
continues to be small but not growth restricted while the
male responds adversely being either growth restricted or
delivered preterm or stillborn [14]. These specific alterations
in development could increase the risk of metabolic disease
in adulthood of children of asthmatic mothers through the
mechanisms we outline below [13, 15–22].
2. Increased Placental Vascular Resistance in
Pregnancies Complicated by Asthma
Animal studies have demonstrated that the placenta is
important in regulating the development of the fetal car-
diovascular system. The placental vascular bed remains in a
predominantly vasodilated state throughout gestation. The
fetal side of the circulation is directly supplied by fetal cardiac
output that is maintained and constant relative to size for
most of the last half of gestation. When there is increased
placental vascular resistance, the fetal heart adjusts its cardiac
output through changes in its growth to maintain a constant
stroke volume and supply to the placenta. In the sheep
model of increased placental vascular resistance there were
significant eﬀects on the fetus including growth restriction,
myocardial hypertrophy, hypoxaemia and hypertension [23].
This study provides evidence that altered placental vascular
function and morphology can have an adverse eﬀect on fetal
cardiovascular development.
Our research has shown that placental vascular structure
and function [15] are significantly altered in the presence of
maternal asthma in a sex-specific manner. In the presence
of maternal asthma placental structure was altered in the
placentae of male fetuses as demonstrated by a significant
decrease in capillary volume [16]. Other structural changes
in the placentae of male fetuses of pregnancies complicated
by asthma where mothers’ were treated with high dose
inhaled corticosteroids included decreased capillary length
and villi length [16]. Placental vascular function studies iden-
tified that both male and female placentae from asthmatic
pregnancies had reduced vasodilatory capacity suggesting the
presence of increased vascular resistance [15]. Increased pla-
cental vascular resistance may have an impact on in utero car-
diovascular development in children of asthmatic mothers.
3. Altered Homeostatic Control in
Pregnancies Complicated by Asthma
Homeostatic controlmay be onemechanism that contributes
to developmental perturbation through altering the set
points for hormonal balance and changing tissue sensitivity
tomany hormones. Prenatal exposure to excessmaternal glu-
cocorticoids is one example of re-setting a homeostatic con-
trol set-point. In the placenta, 11β-hydroxysteroid dehydro-
genase (11β-HSD2) protects the fetus from the potentially
harmful eﬀects of endogenous maternal glucocorticoids, by
acting as a barrier from the much higher levels of cortisol
found in the mother [24]. The main functional isozyme in
the placental syncytiotrophoblast is 11β-HSD2 converting
cortisol to cortisone. Excess glucocorticoids have potentially
adverse eﬀects on the fetus and have been linked to altered
fetal programming which includes decreased growth [25,
26], reduced kidney nephron number [27], and repro-
gramming of the fetal hypothalamic-pituitary adrenal axis
[28]. Several studies have described a relationship between
reduced activity of 11β-HSD2 and reduced birth weight or
intrauterine growth restriction [29, 30].
Excess exposure to glucocorticoids at a critical time point
in kidney development has been shown to reduce nephron
number and predispose an individual to hypertension in
later life [27]. Tang et al. [31] have reported that prenatal
exposure to excess glucocorticoids in the rat model was
associated with salt-sensitive hypertension in adult oﬀspring
due to decreased renal 11β-HSD2. In humans, placental 11β-
HSD2 activity and cortisol exposure in utero were associated
with blood pressure at age 3 years [32]. Each unit increase
in cortisol exposure was associated with 1.6mmHg increase
in blood pressure [32]. Human and animal females are
more susceptible to increased cortisol exposure in utero
and subsequently develop hypertension in adulthood due to
elevation of the renin-angiotensin system [33].
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Our prospective study of pregnant women with asthma
has shown that asthma alone and not the inhaled steroids
used to treat maternal asthma has the greatest eﬀect on
the fetus. We have found that asthmatic women who do
not use inhaled steroids for treatment have smaller female
neonates at term [13]. This late gestation reduction in fetal
growth was associated with a significant decrease in placental
11β-HSD2 activity and a significant decrease in female fetal
adrenal status [13] indicating female babies of asthmatic
mothers are prenatally exposed to higher concentrations of
glucocorticoid which may predispose them to cardiovascular
disease in later life. If mothers’ used inhaled glucocorticoids
to treat their asthma during pregnancy there was a significant
increase in placental 11β-HSD2 activity in placentae of
females. We have also recently identified that inhaled steroids
do not cross the placenta and aﬀect fetal adrenal status
during pregnancy [19] suggesting that only changes in
endogenous maternal cortisol concentrations and adjust-
ments in placental 11β-HSD2 activity influence fetal growth
in pregnancies complicated by asthma. We have recently
reported similar sex specific adjustments in of placental 11β-
HSD2 activity in preterm placentae following exposure to
betamethasone. Placental 11β-HSD2 activity was increased
in female placentae and adrenal status altered but there were
no changes in male placentae [34]. These studies suggest that
in pathological pregnancies the female placenta adjusts 11β-
HSD2 activity in response to the maternal glucocorticoid
environment. However, there are no corresponding data to
indicate that the male placenta has the capacity to adjust
placental 11β-HSD2 activity in response to the maternal
environment. This may be one mechanism that confers a
survival advantage in the female fetus relative to the male
fetus but increases the risk of cardiovascular disease in later
life in females relative to males.
4. Differential Mitochondrial Gene Expression
in Pregnancies Complicated by Asthma
Pathophysiological mechanisms that contribute to the devel-
opment of hypertension and diabetes include impaired
mitochondrial oxidative phosphorylation andmitochondrial
biogenesis which lead to myocardial and endothelial dys-
function [35] and insulin resistance and pancreatic beta
cell failure [36], respectively. Recent placental studies report
that several mitochondrial genes and proteins are altered
in pregnancy complications such as maternal obesity [37],
treatment of maternal HIV infection [38], maternal under-
nutrition [39], and hypoxia [40]. Microarray studies of the
placenta have identified a number of mitochondrial genes are
altered in the presence of maternal asthma during pregnancy
in both males and females [22] including ATP synthase
2B4 (ATP2B4), cytochrome p450 (CYP19A1), catechol-O-
methyltransferase (COMT), coproporphyrinogen oxidase
(CPOX), and malate dehydrogenase 2 (MDH2). Glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) and MDH2 are
enzymes catalyzing reactions in glycolysis and the citric acid
cycle in the mitochondrial metabolic pathway). CPOX has
an important role in heme (Fe) production which is vital
for oxygen transport in the blood. COMT is an enzyme
important for catecholamine metabolism and catabolism
such as for dopamine, noradrenalin, and adrenaline. Some
of these genes were altered sex specifically in the placenta
of asthmatic women, including GAPDH which was only
altered in males, while MDH2, COMT, and CPOX were
decreased in female placentae of pregnancies complicated by
asthma. The presence and absence of inhaled glucocorticoid
use for asthma treatment during pregnancy also influenced
mitochondrial gene expression, with MDH2, COMT, and
CPOX gene expression being increased in placentae of
females whose mothers’ used these inhaled steroids dur-
ing pregnancy. Since it is proposed that programming of
mitochondria is the key adaptation enabling the fetus to
survive in a poor in utero environment [41, 42], alterations
in the expression of each of these genes may contribute to
developmental perturbation in pregnancies complicated by
asthma but this requires further examination.
5. Sex Specific Placental Gene Expression and
Protein Function and Its Relationship to
Fetal Growth in Pregnancies Complicated
by Asthma
Numerous gene changes in placentae of male and female
fetuses of pregnancies complicated by asthma have been
reported [12, 17, 19, 21]. However most of the gene changes
have been observed specifically in the presence of a female
fetus, accompanied by a lower birthweight for this sex.
Global gene changes assessed using microarray identified sex
specific eﬀects, such that female placentae of pregnancies
complicated by asthma had 59 gene changes compared to 6
gene changes in the placentae of males [22]. The main gene
networks altered in the female placentae were genes associ-
ated with inflammation, cellular growth, and proliferation
suggesting these are the pathways that contribute to reduced
growth in females [22]. The diﬀerences in inflammatory
gene expression have also been confirmed showing that
female placentae of pregnancies complicated by asthma have
increased expression of a range of proinflammatory genes
relative to male placentae [17]. Conversely the male fetus
continues to grow normally in the presence of chronic,
maternal asthma [13] due to an increase in the production of
IGF-1 [43] and a limited alteration in global gene expression
[22].
Responsiveness to glucocorticoids and the sensitivity
of the glucocorticoid receptor appear to be central to the
diﬀerences in developmental perturbation in pregnancies
complicated by asthma. Female placental function and
growth appears dependent on exposure to cortisol whereas
males appear glucocorticoid resistant, with the consequence
that cytokine gene expression is dependent on cord blood
cortisol concentrations in females but not in males [17]. We
have reported that female birthweight is negatively correlated
with cord blood cortisol but no such association exists in
males [44]. We initially proposed that these diﬀerences in
the response to cortisol were due to sex specific diﬀerences
in placental GRα, the bioactive isoform of the glucocorticoid
receptor. However in both whole placental tissue [44] and
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in vitro studies [18], GRα protein expression did not vary
with asthma or between the sexes. This diﬀerence may be
conferred by a diﬀerence in placental 11β-HSD2 activity as
we have already discussed, but it may also be related to
diﬀerences in GRα protein function. An alternative explana-
tion is that cytokine gene expression is dependent on cord
blood cortisol concentrations in females but not in males
[17]. It has been observed in in vitro work with placental
explants that female placentae rapidly inhibited placental
cytokine production in the presence of cortisol but this was
not observed inmale placentae, even though receptor protein
levels were the same [18]. There are several isoforms of the
glucocorticoid receptor expressed in the placenta [45] that
may interact with GRα to exert sex specific diﬀerences in
glucocorticoid sensitivity and this is the subject of current
investigations in our laboratory.
Several studies have shown that epigenetic alterations in
GR may contribute to diﬀerences in GR protein expression
[46]. Maternal stress during pregnancy was identified to
contribute to increased methylation of the GR gene and
associated with increased salivary cortisol concentrations in
neonates at 3 months [47]. Dietary protein restriction during
pregnancy in the rat contributed to epigenetic modification
of GR and increased expression of the GR protein in the liver
of oﬀspring [48]. These studies provide evidence that epige-
netic modification of GR may influence protein expression
levels, however, there is no evidence at present to suggest
that placental GR is epigenetically modified in the presence
of maternal asthma because GR protein concentrations do
not vary between groups or sex. Therefore we continue to
focus on post translational modification and GR protein
function.
Sex specific diﬀerences in developmental perturbation
due to diﬀerences in placental gene expression and protein
function in pregnancies complicated by asthma are associ-
ated with developmental perturbation and may contribute
to disease risk in later life. Preliminary evidence in relation
to childhood growth would support this hypothesis.
6. Childhood Growth in Pregnancies
Complicated by Asthma
We have followed a cohort of pregnant women (n = 694)
in Newcastle from 1999 to 2007 and plan to follow up
the children who currently range from the ages 6–13 years.
A great deal of information relating to maternal asthma
severity, asthma treatment used during pregnancy, delivery
details, and neonatal outcomes were collected from this
cohort, and numerous publications have been generated on
maternal health during pregnancy [14, 49–52], placental
function [17, 18, 22], and fetal growth [43]. Our preliminary
investigations of the children in this cohort (conducted at
age 18 months) demonstrated altered growth trajectories
in children whose mothers had asthma during pregnancy.
These data show that while children of nonasthmatic moth-
ers did not deviate from their birth growth trajectory, as
projected from their birth weight centile, 40% of children of
asthmatic mothers had already deviated from this trajectory
at 18 months of age (Figure 1), with the majority (78%)
demonstrating accelerated growth also termed as “catch up
growth.” Interestingly there was a sex diﬀerence in the chil-
dren that were 2 standard deviations away from the predicted
growth trajectory with 60% of females displaying accelerated
growth relative to 40% of males. Children in this preliminary
study were not significantly diﬀerent in relation to mater-
nal and neonatal characteristics including maternal age,
BMI, maternal cigarette use, gravidity, parity, birthweight,
birthweight centile, or placental weight. This group was a
representative sample of the entire cohort.
7. Accelerated Growth and Metabolic Syndrome
Human and animal studies have provided evidence that
low birthweight followed by rapid postnatal weight gain are
associated with adult obesity, diabetes, cardiovascular disease
and premature mortality [8]. Most of the accelerated weight
gain is in the form of adipose tissue rather than lean tissue
with numerous studies reporting deposition predominantly
in the abdomen though usually total body fat is increased
overall [8]. Studies from the UK, Denmark, and Finland
report that adults who were small for gestational age still had
a greater abdominal fat content relative to adults of similar
height, weight, age, and sex [8]. Increased abdominal fat pre-
disposes individuals to an increased risk of hypertension and
diabetes with aging. The presence of abdominal fat increases
sympathetic nervous system activity stimulating activation of
the kidney renin-angiotensin system and causing peripheral
vasoconstriction and hypertension [53]. Other mechanisms
that are altered in utero and may contribute to the devel-
opment of hypertension are microvascular structure and
function [54] and altered hypothalamic-pituitary adrenal
function [55]. The in utero mechanisms that contribute to
subsequent development of type 2 diabetes are proposed to
be epigenetic, specifically related to the histone acetylation
and subsequent suppression of Pdx1, a transcription factor
that is involved in the development of the pancreas especially
in beta cell development [56]. The later development of
insulin resistance and type 2 diabetes is a combination of
increased adiposity leading to increased lipolysis and circu-
lating fatty acids, inflammation, mitochondrial dysfunction
and aberrant insulin signaling [57]. The exact order of
later life events predisposing to diabetes appears uncertain.
However accelerated growth and adiposity are currently the
strongest indicators of risk.
8. Followup Studies of Children from
Pregnancies Complicated by Asthma
The neonatal outcomes of pregnancies complicated by
asthma are now well characterised including birthweight,
hospitalisations, and birth defects. The long-term outcomes
are limited with only two studies that examined the devel-
opment of children of asthmatic mothers. Gordon et al. [58]
reported that there was a significant increase of neurological
abnormalities at 1 year of age in children of asthmatic
mothers with poorly managed asthma. Shatz et al. reported
no diﬀerences between children, at 15 months of age, of
asthmatic women who had well-controlled asthma during
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Figure 1: The association between birth weight centile and child weight centile (measured at 18 months) in children of healthy mothers
(a) and mothers with asthma during pregnancy (b). Data points represent those children whose growth falls within two standard deviations
(solid circles) of the mean growth trajectory, as indicated by the solid line, and those that fall outside of 2 standard deviations (open circles).
pregnancy and non asthmatic women [59]. Both of these
studies did not follow up the children beyond 2 years of age.
It would be important to also determine whether there are
any long term eﬀects of asthma and its treatment on child-
hood development and adult disease risk. Very few studies
have examined children long term to determine when early
pathophysiological changes that result from developmental
perturbation are discernable and there is no evidence in
pregnancies complicated by asthma.
9. Future Studies
Aside from the followup of cohorts of children who were
exposed to maternal asthma during pregnancy to determine
their susceptibility to disease in later life, there are several
unanswered questions in this field. The exact in utero and
early life mechanisms that alter immune, metabolic and
cardiovascular development of oﬀspring of mothers with
asthma and the identification of biological pathways that
could be targeted for preventative interventions are yet to be
described. Some of these areas may be addressed in appro-
priate animal models of asthma which are currently limited
to several murine models [60] and a sheep model [61] of
allergen induced asthma. These models could be adapted for
pregnancy related studies and oﬀspring followup, and used
for the elucidation of mechanisms that contribute to altered
health outcomes as well as to test pregnancy-related or early
life interventions. Animal models of asthmamay also be used
to discern the impact of asthma on child health outcomes
separately from the impact of asthma treatment eﬀects,
which cannot be done in humans for ethical reasons. This
is because it is inappropriate to randomise asthmatic women
to a no asthma treatment regime in order to determine the
eﬀect of asthma alone.
10. Clinical Implications
The current research of the eﬀect of asthma during preg-
nancy on fetal growth and development has identified that
chronic asthma, regardless of its severity, and acute asthma
exacerbations contribute to the poorest outcomes for the
fetus. The use of inhaled corticosteroids to control asthma
during pregnancy protects the fetus from the inflammatory
eﬀects of maternal asthma and reduces the incidence of exac-
erbations which in turn reduces the risk of a poor outcome
for the fetus. This work suggests asthma control, and appro-
priate use of inhaled steroids is an important intervention
in pregnancy. However the long-term eﬀects of asthma and
its treatment on the fetus are yet to be defined.
11. Conclusion
In combination, these studies suggest that the presence
of maternal asthma can impact on fetal growth, neonatal
health, and development. The perturbations observed in
placental function and fetal growth suggest the fetus insti-
tutes a predictive adaptive response to maternal asthma
during pregnancy. The impact of maternal asthma on fetal
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development is sex specific and suggests the female fetus
may be more at risk of metabolic disease as indicated by
greater exposure and sensitivity to changes in glucocorticoid
concentration and accelerated growth in early life relative to
the male. Information from animal studies would suggest
that adult health is significantly aﬀected by these pertur-
bations. However further investigations in human cohorts
are required, and current maternal asthma and pregnancy
cohorts will provide further evidence as children and adult
oﬀspring are studied in the future.
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